Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study
- 1 June 2015
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (7), 1099-1104
- https://doi.org/10.3899/jrheum.141534
Abstract
Objective.To describe the treatment profile of multimorbid patients with rheumatoid arthritis (RA) in contrast to patients with RA only.Methods.COMORA (Comorbidities in Rheumatoid Arthritis) is a cross-sectional, international study assessing morbidities, outcomes, and treatment of patients with RA. Patients were grouped according to their multimorbidity profile assessed by a counted multimorbidity index (cMMI). Treatment for RA was categorized as use of biologic disease-modifying antirheumatic drugs (bDMARD), in particular tumor necrosis factor inhibitors (TNFi), synthetic DMARD (sDMARD) use only, nonsteroidal antiinflammatory drug (NSAID) use, and corticosteroid use. Logistic regression models were performed to determine the OR of bDMARD, TNFi, sDMARD, NSAID, or corticosteroid use based on a patient’s cMMI and global region after adjusting for age, disease activity, disease duration, educational level, and previous DMARD therapy.Results.Out of 3920 patients, 32.7% received bDMARD; 59.9% sDMARD only, 51.1% used concomitant NSAID, and 54.8% used corticosteroid. Regional differences were observed with the most frequent use of bDMARD in the United States (46.5%) and lowest in North Africa (9%). After adjusting for confounders in logistic regression, the OR for bDMARD use was reduced for each additional morbidity (OR 0.89, 95% CI 0.83–0.96). Similar results were found for TNFi (OR 0.91, 95% CI 0.84–0.99), whereas the OR for use of sDMARD was increased (1.13, 95% CI 1.05–1.22). No significant change of OR was found for NSAID or corticosteroid use.Conclusion.In this study, the odds of bDMARD use decreases 11% for each additional chronic morbid condition after adjustment for regional differences, disease activity, and other covariates.This publication has 30 references indexed in Scilit:
- Multimorbidity and rheumatic conditions—enhancing the concept of comorbidityNature Reviews Rheumatology, 2014
- Sociodemographic, Disease, Health System, and Contextual Factors Affecting the Initiation of Biologic Agents in Rheumatoid Arthritis: A Longitudinal StudyArthritis Care & Research, 2013
- Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid ArthritisPLoS Genetics, 2013
- Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?Annals Of The Rheumatic Diseases, 2009
- Missed opportunities in the treatment of elderly patients with rheumatoid arthritisRheumatology, 2009
- Ist das Therapieansprechen bei älteren Patienten mit rheumatoider Arthritis reduziert?Zeitschrift für Rheumatologie, 2008
- The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case–control analysisArthritis & Rheumatism, 2008
- Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?Annals Of The Rheumatic Diseases, 2006
- The Treatment of Unrelated Disorders in Patients with Chronic Medical DiseasesThe New England Journal of Medicine, 1998
- EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITISRheumatology, 1996